Back to search results

IDP-023 for Advanced Blood Cancers

This study is testing a new cell therapy called IDP-023 for people with advanced blood cancers like Non-Hodgkin Lymphoma (NHL) or Multiple Myeloma (MM) that have come back or not responded to previous treatments. IDP-023 uses special immune cells called "natural killer" (NK) cells, which are known to fight cancer. Researchers want to see how safe IDP-023 is, both alone and when given with other antibody therapies like Rituximab or Daratumumab, and if it helps shrink tumors. You might be able to join if you have advanced NHL or MM that has not responded to at least 2 or 3 prior treatments, respectively, and are generally well enough for treatment. The study is currently unclear on its recruitment status.

Study design
This is an open-label study, meaning you and your doctors will know what treatment you are receiving. It's a Phase 1/2 study, starting with a small number of participants (up to 128 planned) to find a safe dose, then expanding to learn more about effectiveness.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to one year after treatment, with specific safety checks for dose-limiting side effects within the first 21 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06119685

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting
PHASE1Ages 18+InterventionalTreatment
Indapta Therapeutics, INC.
~128 participants
Updated 2025-06-03 on ClinicalTrials.gov
What's tested:IDP-023RituximabDaratumumabInterleukin-2CyclophosphamideFludarabine

At a glance

Recruiting sites
9 of 12 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)
Measured over 1 year
+7 more outcomes measured

Conditions

NHL
Multiple Myeloma
Blood Cancer
Refractory Non-Hodgkin Lymphoma
Relapsed Non-Hodgkin Lymphoma
Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Explore related trials

Hematologic NeoplasmMultiple MyelomaNon-Hodgkin Lymphoma

Where it's being run

12 sites across 12 states
California1
Florida1
Georgia1
Minnesota1
New York1
North Carolina1
Ohio1
Oregon1

Study leadership

  • Indapta Therapeutics, Inc. · STUDY_DIRECTOR · Indapta Therapeutics, INC.

Who to contact

Indapta Therapeutics, Inc.
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy.
For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of greater than 12 weeks per the Investigator.

Exclusion

Impaired cardiac function or history of clinical significant cardiac disease.
Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
Active SARS-CoV-2 infection.
Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.

What this trial measures

  • Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)1 year

    Escalation Period

  • Incidence of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)up to 21 days

    Escalation Period

  • Nature of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1)up to 21 days

    Escalation Period

  • Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1)up to 35 days

    Escalation Period

  • Nature of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1)up to 35 days

    Escalation Period

  • Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)1 year

    Escalation Period

  • For MM: Anti-tumor activity by objective response rate (ORR), complete response (CR), stringent complete response (sCR), very good partial response (VGPR), and partial response (PR) - (Phase 2)2 years

    Expansion period

  • For NHL: Anti-tumor activity by objective response rate (ORR) - (Phase 2)2 years

    Expansion period